Trial Profile
A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Halozyme Therapeutics
- 26 Jan 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 30 Sep 2013 Phase Ib results have been presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) according to a Halozyme Therapeutics media release. Results were also summarised in the media release.
- 12 Sep 2013 Results will be presented at the the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), according to a Halozyme Therapeutics media release.